CanDL Database Shines Light on Clinically Important Cancer Gene Mutations

August 27, 2015
Research Lab Facilities Roychondury 1200X900
Sameek Roychowhdury, MD, PhD
  • Many clinical trials use genome sequencing to learn which gene mutations are present in a patient’s tumor cells.

  • But it can be difficult to determine whether there is evidence in the medical literature that a particular mutation might drive cancer growth or be of no consequence.

  • The CanDL database places critical information at the fingertips of researchers and clinicians about known driver mutations, which should hasten drug development and cancer research.

COLUMBUS, Ohio – Many clinical trials use genome sequencing to learn which gene mutations are present in a patient’s tumor cells. The question is important because targeting the right mutations with the right drugs can stop cancer in its tracks. But it can be difficult to determine whether there is evidence in the medical literature that particular mutations might drive cancer growth and could be targeted by therapy, and which mutations are of no consequence.

To help molecular pathologists, laboratory directors, bioinformaticians and oncologists identify key mutations that drive tumor growth in tissues obtained during clinical studies, researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) have designed an online database called the Cancer Driver Log, or CanDL.

The freely accessible database is described in a paper published in the Journal of Molecular Diagnostics. It includes mutations in 60 genes, with 334 distinct variants and 169 unique matching literature references across multiple cancers, as of Aug. 24, 2015.

“Currently, pathology laboratories that sequence tumor tissue must manually research the scientific literature for individual mutations to determine whether they are considered a driver or a passenger to facilitate clinical interpretation,” says Sameek Roychowdhury, MD, PhD. “CanDL expedites this time-consuming process by placing key information about known and possible driver mutations that might be effective targets for drug development at their fingertips,” he says.

“CanDL does not tell doctors what to do—it places the evidence in the scientific literature at their fingertips, enabling them to read and interpret the information themselves.”

Identifying important driver mutations in a patient’s tumor cells can also help reveal why some patients in a clinical trial respond well to a novel agent while others do not respond at all. That information can help improve the effectiveness of existing anticancer drugs, and it can identify subsets of patients who would benefit most from particular therapies.

“Overall, this freely available database will facilitate rapid annotation of cancer genomic testing in molecular pathology labs for mutations,” Roychowdhury says.

Other researchers from Ohio State involved in this study were Senthilkumar Damodaran, Jharna Miya, Esko Kautto, Eliot Zhu, Eric Samorodnitsky, Jharna Datta and Julie W. Reeser.

This work was supported in part by funding from Pelotonia, the Prostate Cancer Foundation, American Cancer Society and the National Human Genome Research Institute.

About The OSUCCC – James

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 44 National Cancer Institute-designated Comprehensive Cancer Centers and one of only four centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer drugs. As the cancer program’s 306-bed adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved Magnet designation, the highest honor an organization can receive for quality patient care and professional nursing practice. At 21 floors with more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care. For more information, please visit cancer.osu.edu.

###

Download a high quality JPEG of Sameek Roychowhdury, MD, PhD.

Contact: Darrell E. Ward, Wexner Medical Center Public Affairs and Media Relations, 614-293-3737, or Darrell.Ward@osumc.edu.

Contact Media Staff

Amanda Harper

Director of Media Relations


614-685-5420 (direct)


614-293-3737 (main)


Amanda.Harper2@osumc.edu


Media staff are available by calling 614-293-3737 Monday through Friday between 8 a.m. and 5 p.m.

 

If after hours, please call 614-293-8000 (ask the operator to page the hospital administrative manager).

Latest News

Hospitals Honor Congressman for Work to Ensure Ohioans Have Access to Specialty Cancer Care

The Alliance of Dedicated Cancer Centers (ADCC) recognized the health care policy and cancer advocacy efforts of U.S. Congressman Pat Tiberi by honoring him with the ADCC Congressional Champions Award.

Pelotonia Fellows Experience the Ride that Funds Their Research

Two Ohio State students and Pelotonia Fellows share their first experiences as participants in the bike ride and fundraiser that provides resources for their cancer research at OSUCCC - James.

Long-Term, High-Dose Vitamin B6/B12 Use Associated With Increased Lung Cancer Risk Among Men

New research suggests long-term, high-dose supplementation with vitamins B6 and B12 — long touted by the vitamin industry for increasing energy and improving metabolism — is associated with a two- to...